Search hospitals > Georgia > Atlanta
Novo Nordisk Investigational Site
Claim this profileAtlanta, Georgia 30318
Global Leader in Diabetes
Global Leader in Type 2 Diabetes
Conducts research for Type 1 Diabetes
Conducts research for Hemostatic Disorders
Conducts research for Blood Clotting Disorders
94 reported clinical trials
0 medical researchers
Summary
Novo Nordisk Investigational Site is a medical facility located in Atlanta, Georgia. This center is recognized for care of Diabetes, Type 2 Diabetes, Type 1 Diabetes, Hemostatic Disorders, Blood Clotting Disorders and other specialties. Novo Nordisk Investigational Site is involved with conducting 94 clinical trials across 42 conditions. There are 0 research doctors associated with this hospital, such as .Top PIs
Clinical Trials running at Novo Nordisk Investigational Site
Hemophilia A
Turner Syndrome
Hemophilia
Non-alcoholic Fatty Liver Disease
Noonan Syndrome
Syndrome
Small for Gestational Age, Turner Syndrome, Noonan Syndrome, Intrauterine Growth Restriction.
Haemophilia A
Diabetes
Type 2 Diabetes
Mim8
for Hemophilia A
This study is looking at how Mim8 works compared to other medicines in children with haemophilia A, who either have inhibitors or do not have inhibitors. Mim8 is a new medicine that will be used for prevention of bleeds. Mim8 will be injected with a thin needle into the skin. The study will last for about 54-98 weeks, from screening to follow-up visit, In case the participant experiences bleeds, these can be treated with additional haemostatic medicine as agreed with the study doctor.
Recruiting2 awards Phase 3
Mim8
for Hemophilia A
This study is looking at how Mim8 works in people with haemophilia A, who either have inhibitors or do not have inhibitors. Mim8 is a new medicine that will be used to avoid bleeding episodes. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). When and how often the participants will receive Mim8 in this study depends on the treatment participant receives in the current Mim8 study participant is taking part in. The study will last for up to 5.5 years. The duration of the study depends on when the participant enrolled in this study. The study will end if Mim8 is approved and marketed in participant's country during the study, or the study will end in 2028, whichever comes first. Mim8 will be injected under the skin with a thin needle either once a week, once every two weeks or once a month. Participants will get up to 262 injections; the number of injections depends on how often participants will get injections. While taking part in this study, there are some restrictions about what medicine participants can use. The study doctor will tell the participants more about this. In case the participants experience bleeds, these can be treated with additional haemostatic medicine as agreed with the study doctor. Female participants cannot take part if they are pregnant, breast-feeding or plan to get pregnant during the study period.
Recruiting2 awards Phase 3
Mim8
for Hemophilia A
This study is investigating how Mim8 works compared to other medicines in people with haemophilia A, who either have inhibitors or do not have inhibitors.
Recruiting2 awards Phase 3
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Novo Nordisk Investigational Site?
Novo Nordisk Investigational Site is a medical facility located in Atlanta, Georgia. This center is recognized for care of Diabetes, Type 2 Diabetes, Type 1 Diabetes, Hemostatic Disorders, Blood Clotting Disorders and other specialties. Novo Nordisk Investigational Site is involved with conducting 94 clinical trials across 42 conditions. There are 0 research doctors associated with this hospital, such as .